How BioMarin and n-Lorem plan to develop an antisense therapy for ReNU syndrome
BioMarin and n-Lorem launch a preclinical antisense program targeting the RNU4-2 variant behind most ReNU syndrome cases.
Pharma & Biotech
BioMarin and n-Lorem launch a preclinical antisense program targeting the RNU4-2 variant behind most ReNU syndrome cases.